Windhover Announces the “Top Biopharma Projects to Watch”

BRIDGEWATER, New Jersey, November 1, 2011 /PRNewswire/ –

– Listed companies to present at Therapeutic Area Partnerships
[http://www.tapartnerships.com ] conference, Boston, November 30 – December
2

Elsevier Business Intelligence [http://www.elsevierbi.com/index.html ]
and Windhover Conferences
[http://www.windhover.com/windhover/content/conferences/index.aspx ] today
announced the Top Projects to Watch
[http://www.windhover.com/content/conferences/TA10-top10.html ] list. The
list delivers projects and companies with high-value assets for partnership,
and with the potential to create future growth through investments in deals.

This year’s list includes a Top 10 in each of six therapeutic areas:
cardiovascular/metabolic, oncology, neuroscience, infectious diseases and
inflammatory/autoimmune, plus a “hot space” category, including
ophthalmology, orphan diseases, and women’s health. The selected companies
have been screened using a strict set of judging criteria, including unmet
medical need, market potential, diversity of indications, strong science,
multi-level partnering opportunities (biotech and pharma), potential for new
opportunities beyond initial indications, and corporate stability.

The top 10 projects chosen to present in each therapeutic area are
selected by a panel of independent experts who screen hundreds of compounds
and weigh their potential as future products. These independent experts
include Campbell Alliance, NI Research, Healogix, Wolpert Associates, Cobbs
Creek Healthcare and Herndon Associates. Senior business development
executives from most of the major pharmaceutical firms as well as management
from innovative biotechnology firms schedule one-on-one partnering meetings.

The complete list of all projects to date is available at

http://www.windhover.com/taprojects

[http://www.windhover.com/content/conferences/TA10-top10.html ]. Each project
has been hand-selected by Windhover’s elite selection panel to ensure a
high-quality slate of presenters.

“This year’s list is handpicked in the six hottest therapeutic areas,”
said David Cassak, VP, Content, for Elsevier Business Intelligence’s
publications. “Many of the companies we selected in the past have gone on to
do big deals, and we expect the same from this years’ companies. 90% of the
companies haven’t presented at major partnering events this year.”

Attendees of the Therapeutic Area Partnerships conference benefit from
expert analysis of trends and opportunities in licensing and M & A
dealmaking, presentations by the industry’s foremost thought leaders and
decision makers, actionable information on emerging, innovative companies
and key licensable projects, strategies to finance and commercialize new
products.

To register, contact Pat Cardone at +1 (203) 840-6269
p.cardone@elsevier.com or register on the Therapeutic Area Partnerships
website at http://www.tapartnerships.com.

About Windhover Conferences and Elsevier Business Intelligence
Windhover Conferences is an Elsevier Business Intelligence company, the
leading provider of business intelligence and analysis to senior executives
in the medical device, pharmaceutical, and biotechnology industries.
Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report,
PharmAsia News, The Tan Sheet”,Start-Up: Emerging Medical Ventures, and The
RPM Report: Regulation – Policy – Market Access, Elsevier Business
Intelligence and Windhover also host a variety of industry meetings and
webinars in both medical device and pharma/biotech, and produce a wide array
of market research reports. For more on the companies’ products and
services, please visit http://www.ElsevierBI.com.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet [http://www.thelancet.com ] and Cell
[http://www.cell.com ], and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
SciVerse ScienceDirect [http://www.sciencedirect.com ], SciVerse Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Nursing Consult
[http://www.nursingconsult.com ], which enhance the productivity of science
and health professionals, and the SciVal suite [http://www.scival.com ] and
MEDai’s Pinpoint Review [http://www.medai.com ], which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier
[http://www.elsevier.com ] employs 7,000 people worldwide. The company is
part of Reed Elsevier Group PLC [http://www.reedelsevier.com ], a
world-leading publisher and information provider, which is jointly owned by
Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock
Exchange).

        Media contact
        Michael Fergus
        +1-908-547-2167
        M.fergus@elsevier.com

SOURCE Elsevier